Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review

About this episode

Dr. McKay discusses androgen pathway-targeting agents and clinical findings from the ESMO Congress 2025.

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here .

People in this episode

Host: Dr. Neil Love

Guest: Dr Rana R McKay

Topics covered

• prostate cancer
• androgen pathway-targeting agents
• clinical findings
• ESMO Congress
• CME information

Keywords

• prostate cancer
• androgen pathway
• clinical findings
• ESMO Congress 2025
• CME

Mentioned in this episode

Organizations: ESMO Congress 2025

More episodes of Prostate Cancer Update

• Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting · June 12, 2026 · 1h 29m
• Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays · June 5, 2026 · 23 min
• Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays · May 26, 2026 · 30 min
• PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida · May 15, 2026 · 52 min
• Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances · April 17, 2026 · 58 min
• Metastatic Bladder Cancer — Rapid Case Review Issue 4 · April 15, 2026 · 28 min